California Rheumatology & Wellness

CLIA Laboratory Citation Details

3
Total Citations
8
Total Deficiencyies
8
Unique D-Tags
CMS Certification Number 05D2117632
Address 7082 N Maple Ave Ste 101, Fresno, CA, 93720
City Fresno
State CA
Zip Code93720
Phone(559) 449-0331

Citation History (3 surveys)

Survey - September 22, 2021

Survey Type: Standard

Survey Event ID: TTOE11

Deficiency Tags: D2123

Summary:

Summary Statement of Deficiencies D2123 HEMATOLOGY CFR(s): 493.851(c) Failure to participate in a testing event is unsatisfactory performance and results in a score of 0 for the testing event. Consideration may be given to those laboratories failing to participate in a testing event only if-- (1) Patient testing was suspended during the time frame allotted for testing and reporting proficiency testing results; (2) The laboratory notifies the inspecting agency and the proficiency testing program within the time frame for submitting proficiency testing results of the suspension of patient testing and the circumstances associated with failure to perform tests on proficiency testing samples; and (3) The laboratory participated in the previous two proficiency testing events. This STANDARD is not met as evidenced by: Based on review of the American Proficiency (API) proficiency testing first event, (Q1) 2021 proficiency testing records, eight (8) random patient test results from 12/20 /2019 to 09/21/2021 and interview with the testing person on 09/22/2121 at 10:30 a. m., it was determined that the laboratory failed to participate in a testing event is unsatisfactory performance and results in a score of 0% for the testing event. The findings included: 1. API reported an unsatisfactory score of 0% for the hematology performance summary event of Q1/2021, which included: erythrocyte (RBC), hemoglobin (HGB), hematocrit (HCT), leukocyte (WBC) count, MCH, MCHC, MCV, platelet count, RDW and white blood (WBC) differential analysis performed on the automated Horiba Micros 60 analyzer. 2. The testing personnel affirmed on 09 /22/2021 at 12:30 p. m. (survey date) that laboratory failed to submit the proficiency challenges for the API proficiency testing event Q1/2021. 3. The laboratory's testing declaration (08/31/2010) reported 20,800 hematology patient tests performed (annually). Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 1 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access

Survey - April 8, 2021

Survey Type: Special

Survey Event ID: D1SE11

Deficiency Tags: D2016 D6000 D2096 D6016

Summary:

Summary Statement of Deficiencies D2016 SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c) (a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS- approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history. This CONDITION is not met as evidenced by: Based on desk review of CMS proficiency testing (PT) records (i.e. CMS CASPER Reports 0155D entitled, "Individual Laboratory Profile" and CMS CASPER Report 0153D entitled, "Unsuccessful (2 of 3) Report"), it was determined that the laboratory failed to successfully participate in a PT program approved by CMS for each analyte or test in which the laboratory is certified under CLIA. The findings included: The laboratory failed to achieve satisfactory performance for the same analyte or test in two out of three consecutive testing events in the specialty of Routine Chemistry constituting unsuccessful PT performance. (See D2096) Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 2 -- D2096 ROUTINE CHEMISTRY CFR(s): 493.841(f) Failure to achieve satisfactory performance for the same analyte or test in two consecutive testing events or two out of three consecutive testing events is unsuccessful performance. This STANDARD is not met as evidenced by: Based on desk review of CMS PT records (CMS CASPER Report 0155D and 0153D, it was determined that the laboratory failed to achieve satisfactory performance for the same analyte or test in two out of three consecutive PT events for the analyte, Sodium (Na), resulting in an "initial" (first) unsuccessful performances. The findings include: a. The laboratory failed to maintain successful performance with the PT program by failing to obtain a score of 80% of acceptable responses in two out of three consecutive PT events for the analyte, Na, as follows: 2020 Q3 2021 Q1 Sodium 60% 60% Q1 = First Testing Event Q3 = Third Testing Event b. Failure to achieve satisfactory performance for the same analyte or test in two out of three consecutive PT resulted in an initial unsuccessful performance for the analyte, Na. D6000 MODERATE COMPLEXITY LABORATORY DIRECTOR CFR(s): 493.1403 The laboratory must have a director who meets the qualification requirements of 493. 1405 of this subpart and provides overall management and direction in accordance with 493.1407 of this subpart. This CONDITION is not met as evidenced by: Based on the severity of the deficiencies cited herein, the Condition: Laboratories Performing Moderate Complexity Testing: Laboratory director was not met. The laboratory director, moderate complexity testing, failed to ensure that PT samples were tested as required under Subpart H of this part. (See D6016) D6016 LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1407(e)(4)(i) The laboratory director is responsible for the overall operation and administration of the laboratory, including the employment of personnel who are competent to perform test procedures, and record and report test results promptly, accurate, and proficiently and for assuring compliance with the applicable regulations. (e) The laboratory director must-- (e)(4)(i) Ensure that the proficiency testing samples are tested as required under Subpart H of this part; This STANDARD is not met as evidenced by: Based on a desk review of CMS PT records, it was determined the laboratory director, moderate complexity testing, failed to ensure that PT samples were tested as required under subpart H. of this part. The findings included: For the analyte, Na, the laboratory repeatedly failed to achieve satisfactory performance for the same analyte or test in two out of three consecutive testing events, resulting in unsuccessful PT performance. (See D2016 and D2096) -- 2 of 2 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access

Survey - August 22, 2019

Survey Type: Standard

Survey Event ID: 4W4111

Deficiency Tags: D2121 D6070 D5217

Summary:

Summary Statement of Deficiencies D2121 HEMATOLOGY CFR(s): 493.851(a) Failure to attain a score of at least 80 percent of acceptable responses for each analyte in each testing event is unsatisfactory analyte performance for the testing event. This STANDARD is not met as evidenced by: Based on review of the first quarter (Q1-2017) of the American Proficiency Institute (API) performance summary report, random patient sampling records and interview with the testing personnel, it was determined that; the laboratory failed to attain a score of at least 80 percent of acceptable responses for Erythrocytes (RBC) and Hematocrit (HCT) analytes. The findings included: a. Q1-2017, API reported the following unsatisfactory proficiency testing scores; Analyte: Score: Event/Year: RBC 60% Q1/2017 HCT 60% Q1-2017 b. For seven (7) out of seven (7) random patient test reports reviewed covering period from 12/18/2017 to 6/18/2019, the laboratory analyzed and reported Complete Blood Count (CBC) during the approximate time the laboratory received the unsatisfactory scores. c. The testing personnel confirmed (8/22 /1029, 1500) that the laboratory received the above unsatisfactory scores. d. Based on the laboratory's annual testing declaration submitted for 2017-2019 the laboratory analyzed and reported approximately 7,800 CBC's which included the RBC counts and HCT analytes. D5217 EVALUATION OF PROFICIENCY TESTING PERFORMANCE CFR(s): 493.1236(c)(1) At least twice annually, the laboratory must verify the accuracy of any test or procedure it performs that is not included in subpart I of this part. This STANDARD is not met as evidenced by: Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 2 -- Based on review of the first quarter (Q1-2017) of the American Proficiency Institute (API) performance summary report, random patient sampling records and interview with the testing personnel, it was determined that; the laboratory failed to at least twice annually, the laboratory must verify the accuracy of any test or procedure it performs that is not included in subpart I of this part. a. Q1-2017, API reported the following unsatisfactory proficiency testing scores; Analyte: Score: Event/Year: MCH 40% Q1/2017 MCHC 40% Q1-2017 Note: Abbreviations: MCH (Mean Corpuscular Hemoglobin) MCHC (Mean Corpuscular Hemoglobin Concentration) b. For seven (7) out of seven (7) random patient test reports reviewed covering period from 12/18 /2017 to 6/18/2019, the laboratory analyzed and reported Complete Blood Count (CBC) during the approximate time the laboratory received the unsatisfactory scores. c. The testing personnel confirmed (8/22/1029, 1500) that the laboratory received the above unsatisfactory scores. d. Based on the laboratory's annual testing declaration submitted for 2017-2019 the laboratory analyzed and reported approximately 7,800 CBC's which included the MCH and MCHC analytes. D6070 TESTING PERSONNEL RESPONSIBILITIES CFR(s): 493.1425(b)(1) Each individual performing moderate complexity testing must follow the laboratory's procedures for specimen handling and processing, test analyses, reporting and maintaining records of patient test results. This STANDARD is not met as evidenced by: Based on review of random patient sampling test results, the laboratory's policy and procedure manual and interview with the testing personnel, it was determined that; the laboratory failed to follow the laboratory's procedures for specimen handling and processing, test analyses, reporting and maintaining records of patient test results. The findings included: a. The laboratory's policy and procedure manual for EDTA Specimens stated: "The ICSH (international Committee for Standardization in Hematology) defines fresh blood specimens as processed within four hours after collection. Whole blood collected in EDTA provides accurate results for all parameters within eight hours of collection. The white cell size distribution may shift when specimens are run between 5 and 25 minutes after collection or more than eight hours after collection-this may affect the automated differential results, and cause instruments flags. Samples are mixed on hematology rocker while awaiting analysis in the laboratory." b. For four (4) out of six (6) random patient test results reviewed covering period from 12/19/2017 to 6/18/2019, three patients were analyzed and reported more than the specified policy and procedure by the laboratory. Following are patient examples: Patient #1 Collection Date/Time : 12/18/2017/10:32 AM Received Date/Time: 12/19/2017/01:17 PM Analyzed Date/Time: 12/19/2017/01:39 PM Patient #2 Collection Date/Time : 04/12/2018/09:32 AM Received Date/Time: 04 /12/2018/09:32 AM Analyzed Date/Time: 04/13/2018/01:08 PM Patient #3 Collection Date/Time : 07/25/2018/10:30 AM Received Date/Time: 07/27/2018/08:59 AM Analyzed Date/Time: 07/27/2018/8:31 AM Patient #4 Collection Date/Time : 07/07 /2019/03:28 AM Received Date/Time: 01/08/2019/10:36 AM Analyzed Date/Time: 01 /08/2019/11:25 AM c. The testing personnel confirmed (8/22/2019, 1500) that the laboratory did not follow its policy and procedure regarding specimens handling processing, test analyses. -- 2 of 2 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access